Aerospan® (flunisolide) – Product Discontinuation

- On January 26, 2018, the FDA announced the discontinuation of Mylan's Aerospan (flunisolide) due to business reasons.
    - The discontinuation is not due to product quality, safety or efficacy concerns.
    - Per Mylan, there is very sparse supply in the market.

- Aerospan is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older; and for asthma patients requiring oral corticosteroid therapy, where adding Aerospan may reduce or eliminate the need for oral corticosteroids.

- Other currently available inhaled corticosteroids indicated for the treatment of asthma include beclomethasone dipropionate (QVAR® Redihaler™), budesonide (Pulmicort Flexhaler™), ciclesonide (Alvesco®), fluticasone furoate (Arnuity™ Ellipta® (fluticasone furoate), fluticasone propionate (ArmonAir™ RespiClick®, Flovent® Diskus®, Flovent® HFA), and mometasone furoate (Asmanex® HFA, Asmanex® Twisthaler®).
    - Refer to individual drug labels for further indication information.